The moves come as Bayer seeks approval from Berkeley leaders for a new 30-year master plan that would allow the Germany-based company to build 1 million square feet of production, research and office space and add some 1,000 employees over that period.
At the forefront of Bayer's big plans are cell therapies, which employ genetically engineered cells to fix blood cancers and potentially more diseases, and one-shot-and-done gene therapies that insert a correct copy of a gene to replace a defective, disease-causing gene.
By Anna Louie Sussman, The New York Times | 04.01.2025
Aggregated News
When Noor Siddiqui was growing up, her mother developed retinitis pigmentosa, a condition that leads to gradual vision loss. When Ms. Siddiqui’s mother was in her 30s, she began going blind. Last summer, Ms. Siddiqui told a podcast host that...
For months, an internet-wide guessing game has swirled around the question of where Elon Musk’s intelligence falls on the bell curve. President Trump has called...
By Peter Wehling, Tino Plümecke, and Isabelle Bartram | 03.26.2025
Biopolitical Times
This article was originally published as “Soziogenomik und polygene Scores” in issue 272 (February 2025) of the German-language journal Gen-ethischer Informationsdienst (GID); translated by the authors.
In mid-November 2024, the British organization Hope not Hate published its investigative research ‘Inside the Eugenics Revival’. In addition to documentating an active international “race research” network, the investigation also brought to light the existence of a US start-up that offers eugenic embryo selection. Heliospect Genomics aims to enable wealthy couples to...
Since Francis Galton coined the phrase “nature versus nurture” 150 years ago, the debate about what makes us who we are has dominated the human sciences.
Do genes determine our destiny, as the hereditarians would say? Or do we enter...
The Center for Genetics and Society is fiscally sponsored by Tides Center, a 501(c)(3) non-profit organization.
Please visit www.tides.org/state-nonprofit-disclosures for additional information.
